Skip to main content
Erschienen in: Supportive Care in Cancer 9/2014

01.09.2014 | Original Article

Risk of unplanned visits for colorectal cancer outpatients receiving chemotherapy: a case-crossover study

verfasst von: Luisa Foltran, Giuseppe Aprile, Federica Edith Pisa, Paola Ermacora, Nicoletta Pella, Emiliana Iaiza, Elena Poletto, Stefania Eufemia Lutrino, Micol Mazzer, Mariella Giovannoni, Giovanni Gerardo Cardellino, Fabio Puglisi, Gianpiero Fasola

Erschienen in: Supportive Care in Cancer | Ausgabe 9/2014

Einloggen, um Zugang zu erhalten

Abstract

Aim

This study was conducted to evaluate the impact of chemotherapy on the risk of unplanned visit in a cohort of colorectal cancer outpatients. Chief complaints for unplanned visits and risk factors for hospital admission were also analyzed.

Patients and methods

Clinical data of 229 consecutive colorectal cancer patients who were unexpectedly presented to our acute oncology clinic between 2006 and 2009 were reviewed. A case-crossover statistical analysis was applied to study the association between exposure to chemotherapy (trigger event) and the occurrence of unplanned visit (acute outcome) in three time windows (7, 15, and 21 days from the closest previous chemotherapy treatment). Cox model was used to assess the risk factors for hospitalization.

Results

There were 469 unplanned visits registered. Most of the patients had Eastern Cooperative Oncology Group performance status (ECOG PS) 0–1 (80 %) and advanced cancer stage (78 %). The majority of unplanned visits (72 %) occurred within 30 days since last chemotherapy. The most frequent presenting complaints were pain, fatigue, and anorexia. The two time windows associated with higher risk of visit were 15 and 21 days from last treatment, both for early (odds ratio [OR] 3.8, CI 1.4–10.2 and OR 3.8, CI 1.4–10.2) and advanced disease stage (OR 1.71, CI 1–2.9 and OR 3, CI 1.5–5.9). Of the unplanned visits, 10 % resulted in hospital admission. Presenting with multiple symptoms and with deteriorated PS were both predictors for hospitalization.

Conclusion

Chemotherapy exposition triggers the need for unplanned visits over the second and third week after treatment. The prompt and effective management of unexpected events may be cost- and time-saving and reduce pressure on oncology services.
Literatur
1.
Zurück zum Zitat Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW (2008) Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 44(10):1345–1389PubMedCrossRef Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW (2008) Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 44(10):1345–1389PubMedCrossRef
2.
Zurück zum Zitat De Angelis R, Grande E, Inghelmann R et al (2007) Cancer prevalence estimates in Italy from 1970 to 2010. Tumori 93:392–397PubMed De Angelis R, Grande E, Inghelmann R et al (2007) Cancer prevalence estimates in Italy from 1970 to 2010. Tumori 93:392–397PubMed
3.
Zurück zum Zitat Mayer DK, Travers D, Wyss A et al (2011) Why do patients with cancer visit Emergency Departments? Results of a 2008 population study in North Carolina. J Clin Oncol 29:2683–2688PubMedCentralPubMedCrossRef Mayer DK, Travers D, Wyss A et al (2011) Why do patients with cancer visit Emergency Departments? Results of a 2008 population study in North Carolina. J Clin Oncol 29:2683–2688PubMedCentralPubMedCrossRef
4.
Zurück zum Zitat Diaz-Couselo FA, O’Connor JM, Nervo A et al (2004) Nonscheduled consultation in oncologic patients. How many of them are true emergencies? An observational prospective study. Support Care Cancer 12:274–277PubMedCrossRef Diaz-Couselo FA, O’Connor JM, Nervo A et al (2004) Nonscheduled consultation in oncologic patients. How many of them are true emergencies? An observational prospective study. Support Care Cancer 12:274–277PubMedCrossRef
5.
Zurück zum Zitat Uramoto H, Iwashige A, Kagami S, Tsukada J (2005) Outpatient treatment for cancer patients at cancer chemotherapy centers in university hospitals. J UOEH 27:359–365PubMed Uramoto H, Iwashige A, Kagami S, Tsukada J (2005) Outpatient treatment for cancer patients at cancer chemotherapy centers in university hospitals. J UOEH 27:359–365PubMed
6.
Zurück zum Zitat Rubenstein EB (1998) Evaluating cost-effectiveness in outpatient management of medical complications in cancer patients. Curr Opin Oncol 10:279–301CrossRef Rubenstein EB (1998) Evaluating cost-effectiveness in outpatient management of medical complications in cancer patients. Curr Opin Oncol 10:279–301CrossRef
7.
Zurück zum Zitat Hassett MJ, O’Malley AJ, Pakes JR et al (2006) Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 98:1108–1117PubMedCrossRef Hassett MJ, O’Malley AJ, Pakes JR et al (2006) Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 98:1108–1117PubMedCrossRef
8.
Zurück zum Zitat McKenzie H, Hayes L, White K et al (2011) Chemotherapy outpatients’ unplanned presentations to hospital: a retrospective study. Support Care Cancer 19:963–969PubMedCrossRef McKenzie H, Hayes L, White K et al (2011) Chemotherapy outpatients’ unplanned presentations to hospital: a retrospective study. Support Care Cancer 19:963–969PubMedCrossRef
9.
Zurück zum Zitat Dodd MJ, Miaskowski C, Paul S (2001) Symptoms clusters and their effect on the functional status of patients with cancer. Oncol Nurs Forum 28:465–470PubMed Dodd MJ, Miaskowski C, Paul S (2001) Symptoms clusters and their effect on the functional status of patients with cancer. Oncol Nurs Forum 28:465–470PubMed
10.
Zurück zum Zitat Aprile G, Ramoni M, Keefe D, Sonis S (2009) Links between regimen-related toxicities in patients being treated for colorectal cancer. Curr Opin Support Palliat Care 3(1):50–54PubMedCrossRef Aprile G, Ramoni M, Keefe D, Sonis S (2009) Links between regimen-related toxicities in patients being treated for colorectal cancer. Curr Opin Support Palliat Care 3(1):50–54PubMedCrossRef
11.
Zurück zum Zitat Lau PM, Stewart K, Dooley M (2004) The ten most common adverse drug reactions (ADRs) in oncology patients: do they matter to you? Support Care Cancer 12:626–633PubMed Lau PM, Stewart K, Dooley M (2004) The ten most common adverse drug reactions (ADRs) in oncology patients: do they matter to you? Support Care Cancer 12:626–633PubMed
12.
Zurück zum Zitat Rothwell PM (2005) External validity of randomised controlled trials: “to whom do the results of this trial apply?”. Lancet 365(9453):82–93PubMedCrossRef Rothwell PM (2005) External validity of randomised controlled trials: “to whom do the results of this trial apply?”. Lancet 365(9453):82–93PubMedCrossRef
13.
Zurück zum Zitat Delea TE, Vera-Llonch M, Edelsberg JS et al (2002) The incidence and cost of hospitalization for 5-FU toxicity among medicare beneficiaries with metastatic colorectal cancer. Value Health 5:35–43PubMedCrossRef Delea TE, Vera-Llonch M, Edelsberg JS et al (2002) The incidence and cost of hospitalization for 5-FU toxicity among medicare beneficiaries with metastatic colorectal cancer. Value Health 5:35–43PubMedCrossRef
14.
Zurück zum Zitat Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, Khayat D (2002) Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 95:155–163PubMedCrossRef Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, Khayat D (2002) Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 95:155–163PubMedCrossRef
15.
Zurück zum Zitat Kleeberg UR, Tews JT, Ruprecht T et al (2005) Patient satisfaction and quality of life in cancer outpatients: results of the PASQOC study. Support Care Cancer 13:303–310PubMedCrossRef Kleeberg UR, Tews JT, Ruprecht T et al (2005) Patient satisfaction and quality of life in cancer outpatients: results of the PASQOC study. Support Care Cancer 13:303–310PubMedCrossRef
16.
Zurück zum Zitat Bang SM, Park SH, Kang HG et al (2005) Changes in quality of life during palliative chemotherapy for solid cancer. Support Care Cancer 13:515–521PubMedCrossRef Bang SM, Park SH, Kang HG et al (2005) Changes in quality of life during palliative chemotherapy for solid cancer. Support Care Cancer 13:515–521PubMedCrossRef
17.
Zurück zum Zitat Morrison V, Henderson BJ, Zinovieff F et al (2012) Common, important, and unmet needs of cancer outpatients. Eur J Oncol Nurs 16:115–123PubMedCrossRef Morrison V, Henderson BJ, Zinovieff F et al (2012) Common, important, and unmet needs of cancer outpatients. Eur J Oncol Nurs 16:115–123PubMedCrossRef
18.
Zurück zum Zitat Aprile G, Pisa FE, Follador A et al (2013) Unplanned presentations of cancer outpatients: a retrospective cohort study. Support Care Cancer 21:397–404PubMedCrossRef Aprile G, Pisa FE, Follador A et al (2013) Unplanned presentations of cancer outpatients: a retrospective cohort study. Support Care Cancer 21:397–404PubMedCrossRef
19.
Zurück zum Zitat Maclure M (1991) The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 133:144–153PubMed Maclure M (1991) The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 133:144–153PubMed
20.
Zurück zum Zitat Maclure M, Mittleman MA (2000) Should we use a case–crossover design? Annu Rev Public Health 21:193–221PubMedCrossRef Maclure M, Mittleman MA (2000) Should we use a case–crossover design? Annu Rev Public Health 21:193–221PubMedCrossRef
21.
Zurück zum Zitat Delaney JA (2009) The case crossover study design in pharmacoepidemiology. Stat Methods Med Res 18:53–65PubMedCrossRef Delaney JA (2009) The case crossover study design in pharmacoepidemiology. Stat Methods Med Res 18:53–65PubMedCrossRef
22.
Zurück zum Zitat Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49:1374–1403PubMedCrossRef Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49:1374–1403PubMedCrossRef
23.
Zurück zum Zitat Song X, Zhao Z, Barber B, Gregory C, Schutt D, Gao S (2011) Characterizing medical care by disease phase in metastatic colorectal cancer. J Oncol Pract 7:25–30CrossRef Song X, Zhao Z, Barber B, Gregory C, Schutt D, Gao S (2011) Characterizing medical care by disease phase in metastatic colorectal cancer. J Oncol Pract 7:25–30CrossRef
24.
Zurück zum Zitat Vera-Llonch M, Weycker D, Glass A et al (2011) Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality. BMC Cancer 11:250PubMedCentralPubMedCrossRef Vera-Llonch M, Weycker D, Glass A et al (2011) Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality. BMC Cancer 11:250PubMedCentralPubMedCrossRef
25.
Zurück zum Zitat Baena-Canada JM, Estalella-Mendoza S, Rosado-Varela P et al (2012) Use of health-care services during chemotherapy for breast cancer. Eur J Cancer 48:3328–3334PubMedCrossRef Baena-Canada JM, Estalella-Mendoza S, Rosado-Varela P et al (2012) Use of health-care services during chemotherapy for breast cancer. Eur J Cancer 48:3328–3334PubMedCrossRef
26.
Zurück zum Zitat Bozdemir N, Eray O, Eken C et al (2009) Demographics, clinical presentations and outcomes of cancer patients admitted to the Emergency Department. Turk J Med Sci 39:235–240 Bozdemir N, Eray O, Eken C et al (2009) Demographics, clinical presentations and outcomes of cancer patients admitted to the Emergency Department. Turk J Med Sci 39:235–240
27.
Zurück zum Zitat De Andrea S, Montanari M, Moja L (2008) Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol 19:1985–1991CrossRef De Andrea S, Montanari M, Moja L (2008) Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol 19:1985–1991CrossRef
28.
Zurück zum Zitat Feyer P, Kleeberg UR, Steingraber M et al (2008) Frequency of side effects in outpatient cancer care and their influence on patient satisfaction—a prospective survey using the PASQOC® questionnaire. Support Care Cancer 16:567–575PubMedCrossRef Feyer P, Kleeberg UR, Steingraber M et al (2008) Frequency of side effects in outpatient cancer care and their influence on patient satisfaction—a prospective survey using the PASQOC® questionnaire. Support Care Cancer 16:567–575PubMedCrossRef
29.
Zurück zum Zitat Curt GA, Breitbart W, Cella D et al (2000) Impact of cancer–related fatigue on the lives of patients: new findings from the fatigue coalition. Oncologist 5:353–360PubMedCrossRef Curt GA, Breitbart W, Cella D et al (2000) Impact of cancer–related fatigue on the lives of patients: new findings from the fatigue coalition. Oncologist 5:353–360PubMedCrossRef
30.
Zurück zum Zitat Hofman M, Morrow GR, Roscoe JA et al (2004) Cancer patients’ expectations of experiencing treatment-related side effects: a University of Rochester Cancer Center-Community Clinical Oncology Program study of 938 patients from community practices. Cancer 101:180–185CrossRef Hofman M, Morrow GR, Roscoe JA et al (2004) Cancer patients’ expectations of experiencing treatment-related side effects: a University of Rochester Cancer Center-Community Clinical Oncology Program study of 938 patients from community practices. Cancer 101:180–185CrossRef
31.
Zurück zum Zitat Aprile G, Ramoni M, Keefe D, Sonis S (2008) Application of distance matrices to define associations between acute toxicities in colorectal cancer patients receiving chemotherapy. Cancer 112(2):284–292PubMedCrossRef Aprile G, Ramoni M, Keefe D, Sonis S (2008) Application of distance matrices to define associations between acute toxicities in colorectal cancer patients receiving chemotherapy. Cancer 112(2):284–292PubMedCrossRef
32.
Zurück zum Zitat Barbera L, Atzema C, Sutradhar R et al (2013) Do patient-reported symptoms predict Emergency Department visits in cancer patients? A population-based analysis. Ann Emerg Med 61:427–437PubMedCrossRef Barbera L, Atzema C, Sutradhar R et al (2013) Do patient-reported symptoms predict Emergency Department visits in cancer patients? A population-based analysis. Ann Emerg Med 61:427–437PubMedCrossRef
33.
Zurück zum Zitat Majem M, Galan M, Perez FJ et al (2007) The oncology acute toxicity unit (OATU): an outpatient facility for improving the management of chemotherapy toxicity. Clin Transl Oncol 9:784–789PubMedCrossRef Majem M, Galan M, Perez FJ et al (2007) The oncology acute toxicity unit (OATU): an outpatient facility for improving the management of chemotherapy toxicity. Clin Transl Oncol 9:784–789PubMedCrossRef
34.
Zurück zum Zitat Molassiotis A, Brearley S, Saunders M et al (2009) Effectiveness of a home care nursing program in the symptom management of patients with colorectal and breast cancer receiving oral chemotherapy: a randomized, controlled trial. J Clin Oncol 27:6191–6198PubMedCrossRef Molassiotis A, Brearley S, Saunders M et al (2009) Effectiveness of a home care nursing program in the symptom management of patients with colorectal and breast cancer receiving oral chemotherapy: a randomized, controlled trial. J Clin Oncol 27:6191–6198PubMedCrossRef
Metadaten
Titel
Risk of unplanned visits for colorectal cancer outpatients receiving chemotherapy: a case-crossover study
verfasst von
Luisa Foltran
Giuseppe Aprile
Federica Edith Pisa
Paola Ermacora
Nicoletta Pella
Emiliana Iaiza
Elena Poletto
Stefania Eufemia Lutrino
Micol Mazzer
Mariella Giovannoni
Giovanni Gerardo Cardellino
Fabio Puglisi
Gianpiero Fasola
Publikationsdatum
01.09.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 9/2014
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-014-2234-z

Weitere Artikel der Ausgabe 9/2014

Supportive Care in Cancer 9/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.